Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

FTSE 100 gains on upbeat AstraZeneca results

Published 11/02/2021, 09:13
Updated 11/02/2021, 09:18
© Reuters.

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)
* FTSE 100 up 0.2%, FTSE 250 flat

Feb 11 (Reuters) - London's FTSE 100 gained on Thursday
boosted by drugmaker AstraZeneca (NASDAQ:AZN)'s upbeat quarterly results and
as information group Relx planned to raise its dividend.
COVID-19 vaccine maker AstraZeneca AZN.L rose 1.1% and was
the top boost to the FTSE 100 after it beat analyst's estimates
for fourth-quarter product sales and also forecast revenue
growth in 2021. The blue-chip FTSE 100 index .FTSE rose 0.2%, with
automakers .FTNMX3350 and mining stocks .FTNMX1770 leading
gains. The mid-cap index .FTMC was flat.
Weighing on sentiment was a sharp drop in Britain's housing
market in January as the country went back into a coronavirus
lockdown and as a tax break for buyers neared its expiry, a
survey showed. Homebuilder stocks .FTNMX3720 dropped 0.2%.
European information business provider Relx REL.L gained
1.2% after it said it planned to raise its dividend by 3% after
predicting a return to pre-COVID-19 profit trends in
2021. Retailer Ted Baker TED.L plunged 6% after reporting a 47%
fall in fourth-quarter revenue, as stores in Britain were shut
during the latest coronavirus lockdown and due to weak demand
during the Christmas season.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.